$0

Kymriah Receives FDA Approval for R/R FL After Two or More Lines of Systemic Therapy

Late on Friday, May 27, Novartis announced (press release) that the FDA granted accelerated approval for Kymriah (CD19 CAR-T) in ≥3L r/r FL. Kymriah is the second CAR-T to be approved by the FDA in r/r FL. Of note, Kymriah’s FDA approval was based on results from the Ph2 ELARA trial, with 86% and 68% of patients achieving an ORR and CR, respectively. The Celltelligence team will be conducting a full thoughts-on analysis and label review in the coming days (link to PI).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.